Sichuan Kelun Pharmaceutical , Ltd. Class A EBIT

The latest EBIT for 002422.SZ is $2B as of September 2026. That compares with $2.1B in the prior-year period — down 3.0% year over year. That is below the Healthcare sector average of $99B. Investors often review this figure alongside Sichuan Kelun Pharmaceutical , Ltd. Class A's historical trend and sector peers before judging valuation or financial health.

Over the past year, 002422.SZ's EBIT moved from $2.1B to $2B — a 3.0% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Sichuan Kelun Pharmaceutical , Ltd. Class A's operating scale or balance-sheet position.

Against Healthcare companies, 002422.SZ currently prints $2B for EBIT, while the sector average sits near $99B. That is roughly 97.9% below the sector mean. Large gaps often invite a closer look at Sichuan Kelun Pharmaceutical , Ltd. Class A's growth, margins, and balance sheet.

A EBIT figure of $2B for 002422.SZ is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $99B. Explore the charts below for those layers of context.

After noting 002422.SZ's EBIT ($2B), review year-over-year change from $2.1B, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.